MCID: SVR005
MIFTS: 49

Severe Pre-Eclampsia

Categories: Cardiovascular diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Severe Pre-Eclampsia

MalaCards integrated aliases for Severe Pre-Eclampsia:

Name: Severe Pre-Eclampsia 12 54 15 71 32
Severe Preeclampsia 12 15
Severe Pre-Eclampsia, Antepartum Condition or Complication 71
Severe Pre-Eclampsia, Postpartum Condition or Complication 71
Severe Pre-Eclampsia, with Delivery 12
Antepartum Severe Pre-Eclampsia 12
Postpartum Severe Pre-Eclampsia 12
Severe Toxemia 71

Classifications:



External Ids:

Disease Ontology 12 DOID:13129
ICD9CM 34 642.50
ICD10 32 O14.1
UMLS 71 C0156669 C0156672 C0156673 more

Summaries for Severe Pre-Eclampsia

Disease Ontology : 12 A pre-eclampsia that has symptom at least one of the following: SBP of 160mm HG or higher or DPB of 110mm HG or higher on 2 occasions at least 6 hours apart, proteinuria more than 5g in a 24-hour collection, pulmonary edema or cyanosis, oliguria, persistent headaches, epigastric pain and/or impaired liver function, thrombocytopenia, oligohydramnios, decreased fetal growth or placental abruption.

MalaCards based summary : Severe Pre-Eclampsia, also known as severe preeclampsia, is related to eclampsia and acute kidney failure, and has symptoms including at least one of the following An important gene associated with Severe Pre-Eclampsia is HLA-G (Major Histocompatibility Complex, Class I, G), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Staphylococcus aureus infection. The drugs Dalteparin and Pseudoephedrine have been mentioned in the context of this disorder. Affiliated tissues include placenta, liver and endothelial, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Severe Pre-Eclampsia

Diseases in the Eclampsia family:

Pre-Eclampsia Severe Pre-Eclampsia

Diseases related to Severe Pre-Eclampsia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 350)
# Related Disease Score Top Affiliating Genes
1 eclampsia 31.3 VEGFA SERPINC1 PGF PAPPA LGALS13 HLA-G
2 acute kidney failure 31.1 GPT CFH ALB
3 thrombotic microangiopathy 30.9 VEGFA CFH
4 pericardial effusion 30.7 VEGFA GPT ALB
5 hemolytic-uremic syndrome 30.6 CFH CFB C3
6 enterocolitis 30.6 CFH CFB C3
7 mild pre-eclampsia 30.6 VEGFA VCAM1 PGF PAPPA LGALS13 LEP
8 patau syndrome 30.6 PGF PAPPA LGALS13
9 hyperuricemia 30.4 LEP GPT ALB
10 membranoproliferative glomerulonephritis 30.4 CFH CFB C3 ALB
11 hypertensive encephalopathy 30.4 VEGFA PGF ALB
12 hellp syndrome 30.4 VEGFA SERPINC1 PGF LGALS13 LEP GPT
13 brain edema 30.3 VEGFA MMP9 ALB
14 cholelithiasis 30.3 LEP GPT ALB
15 kidney disease 30.2 VEGFA VCAM1 LEP CFH C3 ALB
16 leptin deficiency or dysfunction 30.2 LEP GPT ALB
17 antiphospholipid syndrome 30.2 VCAM1 SERPINC1 PGF F5 CFH C3
18 glomerulonephritis 30.2 VCAM1 FN1 CFH C3 ALB
19 proteasome-associated autoinflammatory syndrome 1 30.1 VCAM1 MMP9 ALB
20 disseminated intravascular coagulation 30.1 SERPINC1 GPT FN1 F5
21 amaurosis fugax 29.9 MMP9 F5
22 liver cirrhosis 29.9 SERPINC1 LEP GPT ALB
23 hemolytic anemia 29.8 CFH CFB C3 APOH
24 purpura 29.8 SERPINC1 C3 APOH
25 placental insufficiency 29.7 VEGFA SERPINC1 PGF PAPPA LEP FGR
26 cardiovascular system disease 29.6 VCAM1 SERPINC1 LEP APLN ALB
27 polyarteritis nodosa 29.6 VCAM1 GPT APOH
28 thrombotic thrombocytopenic purpura 29.5 SERPINC1 CFH C3 APOH
29 autoimmune disease 29.4 VCAM1 MMP9 HLA-G C3 APOH
30 thrombophilia due to thrombin defect 29.3 SERPINC1 F5 APOH
31 pre-eclampsia 29.2 VEGFA VCAM1 SERPINC1 PGF PAPPA MMP9
32 papilledema 29.1 VEGFA SERPINC1 APOH ALB
33 placental abruption 29.1 SERPINC1 PGF PAPPA HLA-G F5 APOH
34 hepatic infarction 29.1 SERPINC1 GPT APOH ALB
35 endocarditis 29.0 VCAM1 SERPINC1 APOH ALB
36 pulmonary embolism 29.0 SERPINC1 F5 APOH ALB
37 thrombophilia due to activated protein c resistance 28.9 SERPINC1 F5 APOH
38 antithrombin iii deficiency 28.9 SERPINC1 F5 APOH
39 hypertension, essential 28.8 VEGFA VCAM1 SERPINC1 PGF PAPPA MMP9
40 thrombosis 28.8 VCAM1 SERPINC1 F5 APOH
41 intracranial hypertension 28.8 SERPINC1 F5 APOH ALB
42 homocysteinemia 28.7 VCAM1 SERPINC1 F5 APOH ALB
43 protein s deficiency 28.7 SERPINC1 F5 APOH
44 thrombocytopenia 28.7 SERPINC1 GPT F5 CFH CFB C3
45 budd-chiari syndrome 28.6 SERPINC1 F5 APOH
46 blood coagulation disease 28.5 VEGFA SERPINC1 GPT F5 APOH ALB
47 stroke, ischemic 28.2 SERPINC1 MMP9 F5 APOH ALB
48 placenta disease 28.1 VEGFA SERPINC1 PGF PAPPA HLA-G F5
49 vascular disease 27.8 VEGFA VCAM1 SERPINC1 MMP9 LEP FN1
50 dipetalonemiasis 10.6 GPT ALB

Graphical network of the top 20 diseases related to Severe Pre-Eclampsia:



Diseases related to Severe Pre-Eclampsia

Symptoms & Phenotypes for Severe Pre-Eclampsia

Symptoms:

12
  • at least one of the following

MGI Mouse Phenotypes related to Severe Pre-Eclampsia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.35 ALB APLN C3 CFB CFH F5
2 homeostasis/metabolism MP:0005376 10.31 ALB APLN APOH C3 CFB CFH
3 immune system MP:0005387 10.18 ALB C3 CFB CFH FGR FN1
4 hematopoietic system MP:0005397 10.17 C3 CFB CFH FGR FN1 HLA-G
5 embryo MP:0005380 10.11 APLN C3 F5 FN1 LEP PGF
6 liver/biliary system MP:0005370 9.87 ALB C3 F5 FN1 LEP SERPINC1
7 muscle MP:0005369 9.86 ALB APLN C3 CFH FN1 LEP
8 normal MP:0002873 9.81 ALB C3 CFB CFH FGR FN1
9 renal/urinary system MP:0005367 9.56 ALB C3 CFB CFH LEP MMP9
10 skeleton MP:0005390 9.28 C3 CFB FGR FN1 GPT LEP

Drugs & Therapeutics for Severe Pre-Eclampsia

Drugs for Severe Pre-Eclampsia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 158)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dalteparin Approved Phase 4 9005-49-6
2
Pseudoephedrine Approved Phase 4 90-82-4 7028
3
Ephedrine Approved Phase 4 299-42-3 9294
4
Enoxaparin Approved Phase 4 9005-49-6 772
5
leucovorin Approved Phase 4 58-05-9 6006 143
6
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
7
Clonidine Approved Phase 4 4205-90-7 2803
8
Captopril Approved Phase 4 62571-86-2 44093
9
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
10
Azithromycin Approved Phase 4 83905-01-5 55185 447043
11
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
12 Pharmaceutical Solutions Phase 4
13 Antibodies Phase 4
14 Immunoglobulins Phase 4
15 Antibodies, Antiphospholipid Phase 4
16 Anti-Infective Agents Phase 4
17 Heparin, Low-Molecular-Weight Phase 4
18 Adrenergic Agonists Phase 4
19 Adrenergic alpha-2 Receptor Agonists Phase 4
20 Sympatholytics Phase 4
21 Central Nervous System Stimulants Phase 4
22 Vasoconstrictor Agents Phase 4
23 Trace Elements Phase 4
24 Micronutrients Phase 4
25 Vitamin B Complex Phase 4
26 Vitamin B9 Phase 4
27 Nutrients Phase 4
28 Hematinics Phase 4
29 Folate Phase 4
30 Natriuretic Agents Phase 4
31 diuretics Phase 4
32 Sodium Potassium Chloride Symporter Inhibitors Phase 4
33 Angiotensin-Converting Enzyme Inhibitors Phase 4
34 Iron Supplement Phase 4
35 Lactoferrin Phase 4
36 Anti-Asthmatic Agents Phase 4
37 Respiratory System Agents Phase 4
38 Nasal Decongestants Phase 4
39 Bronchodilator Agents Phase 4
40
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
41
Misoprostol Approved Phase 3 59122-46-2 5282381
42
Oxytocin Approved, Vet_approved Phase 3 50-56-6 439302 53477758
43
Carbetocin Approved, Investigational Phase 3 37025-55-1 71715 16681432
44
Digoxin Approved Phase 2, Phase 3 20830-75-5 30322 2724385
45
Nicardipine Approved, Investigational Phase 3 55985-32-5 4474
46
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
47
Titanium dioxide Approved Phase 3 13463-67-7
48
Povidone Approved Phase 3 9003-39-8
49
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
50 Urapidil Investigational Phase 3 34661-75-1

Interventional clinical trials:

(show top 50) (show all 116)
# Name Status NCT ID Phase Drugs
1 Effectiveness Of Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia: Randomized Placebo-Controlled Clinical Trial Unknown status NCT01361425 Phase 4 methildopa;placebo
2 Continuation Versus Discontinuation of Magnesium Sulfate After Delivery in Women With Severe Preeclampsia. A Randomized Controlled Trial Unknown status NCT03318211 Phase 4 Magnesium Sulfate
3 Postpartum Prophylaxis With Short Course Magnesium Sulfate in Severe Preeclampsia: a Randomized Clinical Trial Completed NCT01408979 Phase 4 Magnesium sulfate 12 hours;Magnesium sulfate 24 hours
4 A Randomized Open-label Study to Compare the Clinical Outcomes and Magnesium Serum Concentrations Obtained in the Treatment of Severe Preeclampsia With a Repeat Bolus Intravenous Magnesium Sulfate Regimen Administered With the Springfusor Infusion Pump to a Continuous Intravenous Magnesium Sulfate Regimen Completed NCT02091401 Phase 4 Magnesium Sulfate
5 Low Molecular Weight Heparin for Treatment of Recurrent Miscarriage With Negative Antiphospholipid Antibodies: a Randomized Controlled Trial Completed NCT01608347 Phase 4 LMWH+Folic acid;Folic Acid
6 Effectiveness of Postpartum Furosemide on Recovery Blood Pressure in Puerperal Women With Severe Preeclampsia: a Randomized Clinical Trial Completed NCT02163655 Phase 4 FUROSEMIDE;Placebo
7 Randomized Clinical Trial for Effectiveness of Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure Completed NCT01761916 Phase 4 CLONIDINE;CAPTOPRIL
8 Evaluation of Dose-response Effect of Acetylsalicylic Acid on Placental Development, Preterm Birth, Fetal Growth and Hypertension in Pregnancy in Women With Previous History of Preeclampsia Completed NCT01352234 Phase 4 Acetylsalicylic Acid 160 mg;Acetylsalicylic Acid 80 mg
9 Phase IV Study of Oral Administration of Bovine Lactoferrin (bLf) to Prevent and Cure Iron Deficiency (ID) and Iron Deficiency Anemia (IDA) Until Delivery in Hereditary Thrombophilia (HT) Affected Pregnant Women Completed NCT01221844 Phase 4 FerroGrad by Abbott
10 Prophylactic Ephedrine to Reduce Fetal Bradycardia After Combined Spinal Epidural Labor Analgesia: a Randomized Double Blind Placebo-controlled Study Completed NCT02062801 Phase 4 Ephedrine;Placebo
11 Efficacy and Safety of One Gram Versus Two Grams Intravenous Maintenance Dose of Magnesium Sulfate in Women With Severe Pre-eclampsia: a Randomized Clinical Trial. Recruiting NCT03164304 Phase 4 Magnesium Sulfate
12 Impact of Antichlamydial Treatment on the Rate of Preeclampsia Among Egyptian Primigravidae: a Randomized Controlled Trial Recruiting NCT03233880 Phase 4 Azithromycin 1gm
13 Effectiveness and Safety of 1g/Hour vs. 2g/Hour of Magnesium Sulfate Maintenance Dose for Eclampsia Prevention: Randomized Clinical Trial Terminated NCT02396030 Phase 4 Magnesium sulfate 50% - 1g/h;Magnesium sulfate 50% - 2g/h
14 Clinical Effect of Atenativ Treatment on Uterine Blood Flow and the Amount of Atenativ Needed to Maintain a Normal Antithrombin Lvels During Two Weeks in Early and Severe Preeclampsia Withdrawn NCT02278575 Phase 4 Atenativ
15 Oral Nifedipine Versus IV Labetalol in Treatment of Severe Pre Eclampsia in Pregnancy Unknown status NCT03325348 Phase 2, Phase 3 Nifedipine 10 mg;Labetalol
16 Carbetocin Versus Oxytocin for Prevention of Postpartum Hemorrhage in Patients With Severe Preeclampsia: a Double Blind Randomized Controlled Trial Unknown status NCT01382732 Phase 3 Carbetocin;Oxytocin
17 Use of Sildenafil Citrate in Management of Mild Pre-eclampsia: A Randomized Controlled Trial Unknown status NCT03262961 Phase 2, Phase 3 Sildenafil 20 MG;Placebo Oral Tablet
18 Carbetocin in Preventing Postpartum Bleeding in Women With Severe Preeclampsia. Completed NCT02086994 Phase 3 misoprostol;carbetocin
19 Ibuprofen Versus Acetaminophen in Women With Severe Pre-eclampsia After Vaginal Delivery. Completed NCT01988298 Phase 2, Phase 3 Ibuprofen;Acetaminophen
20 The Best Magnesium Sulphate Protocol for Severe Pre-eclampsia : A Randomized Controlled Trial Completed NCT01846156 Phase 3 MgSO4
21 A Novel Protocol for Postpartum Magnesium Sulfate in Severe Preeclampsia When the Woman Received Less That 8 Hours Before Delivery. Six Versus Twenty-four Hours Postpartum Completed NCT02317146 Phase 2, Phase 3 Magnesium Sulfate
22 Magnesium Sulfate During the Postpartum in Women With Severe Preeclampsia Receiving Treatment for More Than 8 Hours Before Delivery. A Randomized Multicenter Clinical Trial . Completed NCT02307201 Phase 2, Phase 3 Magnesium Sulfate
23 Low Molecular Weight Heparin, Enoxaparin, to Prevent Adverse Maternal and Perinatal Outcomes in Women With Previous Severe Preeclampsia at Less Than 34 Weeks' Gestation. A Prospective Randomized Trial Completed NCT00986765 Phase 3 Lovenox® (enoxaparin);Aspegic ® (Aspirin)
24 Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy and Death in Preterm Infants (MASP-STUDY) Completed NCT01492608 Phase 3 Magnesium sulphate
25 A Phase 2b/3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of AMAG-423, a Digoxin Immune Fab, in Antepartum Subjects With Severe Preeclampsia Recruiting NCT03008616 Phase 2, Phase 3
26 A Phase 3, Randomized, Placebo-controlled, Double Blind Study of KW-3357 in Patients With Early Onset Severe Preeclampsia Recruiting NCT04182373 Phase 3 Antithrombin gamma;physiological saline
27 The Treatment of Hypertension Associated With Severe Preeclampsia. A Randomize Controlled Trial of Urapidil Versus Nicardipine. The Uranic Trial Active, not recruiting NCT02558023 Phase 3 Urapidil;Nicardipine
28 Interest of Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care: Multicentric Randomized Controlled Trial Not yet recruiting NCT03237819 Phase 3 Sulfate, Magnesium;Placebo - Concentrate
29 Investigating the Role of Early Low-dose Aspirin in Diabetes: A Phase III Multicentre Double-blinded Placebo-controlled Randomised Trial of Low-dose Aspirin Initiated in the First Trimester of Diabetes Pregnancy Not yet recruiting NCT03574909 Phase 3 Aspirin;Placebos
30 Maternal and Neonatal Outcomes After the Use of Vasopressors to Correct Hypotension During Cesarean Section Under Spinal Anesthesia in Pregnant Women With Severe Preeclampsia: Randomized Clinical Trial Withdrawn NCT01451060 Phase 3 Metaraminol;Ephedrine
31 Utility of Tocolytic Therapy for Maintenance Tocolysis in the Management of Threatened Preterm Delivery Withdrawn NCT01796522 Phase 3 progesterone 200 mg / day vaginally;nifedipine (60 mg / day orally)
32 Labetalol Versus MgSO4 for the Prevention of Eclampsia Trial (LAMPET) Withdrawn NCT00293735 Phase 2, Phase 3 labetalol (seizure prevention);MgSO4 (seizure prevention)
33 Rosuvastatin Use in Order to Induce Preeclampsia Resolution in Severe Preeclampsia Cases up to 48 Hours Following Delivery Unknown status NCT02314286 Phase 1, Phase 2 Rosuvastatin;Placebo
34 A Parallel, Double-blind, Placebo Controlled, Randomized Comparison of an Anti-digoxin Antibody (Digibind) Versus Placebo for the Treatment of Antepartum Patients With Severe Preeclampsia Completed NCT00158743 Phase 2 Anti-digoxin antibody (FAB fragment)
35 Comparison Between Dexmedetomidine and Remifentanil on the Maternal Responses to Tracheal Intubation in Severe Pre-eclamptic Patients During Caesarean Delivery Completed NCT01766089 Phase 2 Remifentanil;Dexmedetomidine
36 Sleep Disordered Breathing and Preeclampsia Completed NCT00259688 Phase 2
37 Randomized Controlled Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients at a Tertiary Care Hospital of Karachi. Completed NCT02050529 Phase 2 Labetalol;Hydralazine
38 Low-Dose Aspirin in the Postpartum Period and Endothelial Function in Patients With Preeclampsia Recruiting NCT03667326 Phase 2 Aspirin;Placebo oral capsule
39 Preeclampsia And Nonsteroidal Drugs for Analgesia (PANDA): a Randomized Non Inferiority Trial Recruiting NCT03978767 Phase 2 Ibuprofen 600 mg;Ketorolac;Acetaminophen;Oxycodone
40 Pravastatin to Prevent Preeclampsia and Reduce Maternal-Neonatal Mortality and Morbidity in High Risk Preeclampsia Patients Recruiting NCT03648970 Phase 2 Pravastatin
41 Certolizumab to Prevent Pregnancy Complications in High-Risk Patients With APS or SLE - (IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy) Recruiting NCT03152058 Phase 2 Certolizumab Pegol
42 Usefulness of Extracorporeal Removal of sFlt-1 in Women With Severe Preeclampsia at Less Than 26 Weeks' Gestation Terminated NCT02286284 Phase 2
43 Effects of Vitamin C Administration on Extravascular Lung Water in Patients With Severe Features of Preeclampsia: a Randomized, Placebo-controlled Trial Completed NCT03451266 Phase 1 Vitamin C;placebo
44 A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety of Recombinant Human Relaxin (rhRlx) in Subjects With Preeclampsia Suspended NCT00333307 Phase 1 recombinant human relaxin
45 Prognostic Value of Ambulatory Blood Pressure Monitoring Pattern in Post-Partum Pre-Eclamptic Patients Unknown status NCT02943122
46 Antiphospholipid Antibodies and Early Severe Preeclampsia (< 34 Weeks of Gestation). A Case-Control Study. Unknown status NCT01538121
47 Spinal Anesthesia in Severe Preeclampsia and Its Impact on Hemodynamics (Case Control Study) Unknown status NCT02633995
48 CA-125 and Severity of Pre-Eclampsia Unknown status NCT02704676
49 Effect of Treatment of Vitamin D Deficiency During Pregnancy on Hypocalcemia Unknown status NCT02021864 vitamin D3 50,000 unit;prenatal multivitamin
50 Random Urine Protein-creatinine Ratio to Predict Magnitude of Proteinuria in Different Severity of Pre-eclamptic Patients Unknown status NCT01623791

Search NIH Clinical Center for Severe Pre-Eclampsia

Genetic Tests for Severe Pre-Eclampsia

Anatomical Context for Severe Pre-Eclampsia

MalaCards organs/tissues related to Severe Pre-Eclampsia:

40
Placenta, Liver, Endothelial, Kidney, Heart, Testes, Lung

Publications for Severe Pre-Eclampsia

Articles related to Severe Pre-Eclampsia:

(show top 50) (show all 3625)
# Title Authors PMID Year
1
The 3'-untranslated region of the HLA-G gene in relation to pre-eclampsia: revisited. 54 61
20070604 2010
2
Soluble human leukocyte antigen-G isoforms in maternal plasma in early and late pregnancy. 54 61
19811467 2009
3
Is there any link between severe pre-eclampsia and defined polymorphisms in leptin and adiponectin genes? 54 61
18958929 2008
4
Antithrombin improves fetal condition in women with severe pre-eclampsia before 32 weeks of gestation; a randomized, double-blind, placebo-controlled trial. 54 61
18226126 2008
5
Effect of sera on the adhesion of natural killer cells to the endothelium in severe pre-eclampsia. 54 61
16984509 2006
6
[Expression of Fas antigen and ligand, placental growth factor in placenta of pregnant women with pre-eclampsia]. 54 61
15938782 2005
7
Maternal and fetal single nucleotide polymorphisms in the epoxide hydrolase and gluthatione S-transferase P1 genes are not associated with pre-eclampsia in the Coloured population of the Western Cape, South Africa. 54 61
16147638 2004
8
Recent progress in the therapeutic management of pre-eclampsia. 54 61
15500369 2004
9
Serum leptin levels and uterine Doppler flow velocimetry at 20 weeks' gestation as markers for the development of pre-eclampsia. 54 61
15697078 2004
10
Serum levels of leptin, insulin-like growth factor-I and insulin-like growth factor binding protein-3 in women with pre-eclampsia, and their relationship to insulin resistance. 54 61
15497497 2004
11
Serum levels of insulin, IGF-1, and IGFBP-1 in pre-eclampsia and eclampsia. 54 61
15001368 2004
12
Antinuclear antibody testing in obstetric patients. 54 61
14750494 2003
13
Factor V Leiden and prothrombin G20210A mutations in pregnancies with adverse outcome. 54 61
12572596 2002
14
Is there an increased maternal-infant prevalence of Factor V Leiden in association with severe pre-eclampsia? 54 61
11888101 2002
15
The expression and activity of monoamine oxidase A, but not of the serotonin transporter, is decreased in human placenta from pre-eclamptic pregnancies. 54 61
11133008 2000
16
Transport and metabolism of serotonin in the human placenta from normal and severely pre-eclamptic pregnancies. 54 61
10729753 2000
17
Lack of human leukocyte antigen-G expression in extravillous trophoblasts is associated with pre-eclampsia. 54 61
10611266 2000
18
Studies on the HLA-DRB1 genotypes in Japanese women with severe pre-eclampsia positive and negative for anticardiolipin antibody using a polymerase chain reaction-restriction fragment length polymorphism method. 54 61
10601082 1999
19
Vascular cell adhesion molecule-1 (VCAM-1) and leukocyte activation in pre-eclampsia and eclampsia. 54 61
9856316 1998
20
Detection of factor V Leiden mutation in severe pre-eclamptic Hungarian women. 54 61
9712539 1998
21
Abnormal expression of plasminogen activator inhibitors in patients with gestational trophoblastic disease. 54 61
8863672 1996
22
Insulin-like growth factors and their binding proteins in normal and abnormal human fetal growth. 54 61
7532055 1994
23
Lupus anticoagulant in pre-eclampsia and intra-uterine growth retardation. 54 61
1773868 1991
24
Postpartum length of stay and risk for readmission among women with preeclampsia. 61
30122116 2020
25
Placental fractalkine immunoreactivity in preeclampsia and its correlation with histopathological changes in the placenta and adverse pregnancy outcomes. 61
30049235 2020
26
Factors contributing to favourable neonatal outcomes in early-onset severe preeclampsia. 61
32027191 2020
27
Up-regulation of PTEN via LPS/AP-1/NF-κB pathway inhibits trophoblast invasion contributing to preeclampsia. 61
31896494 2020
28
The potential contribution of stromal cell-derived factor 2 (SDF2) in endoplasmic reticulum stress response in severe preeclampsia and labor-onset. 61
30776414 2020
29
Maternal and perinatal outcomes related to superimposed pre-eclampsia in a Brazilian cohort of women with chronic hypertension. 61
32037536 2020
30
A challenging case of twin pregnancy with complete hydatidiform mole and co-existing normal live fetus - A case report and review of the literature. 61
31890831 2020
31
Selective feticide as a treatment of severe preeclampsia in discordant twins. 61
31499281 2020
32
Copper and ceruloplasmin levels are closely related to the severity of preeclampsia. 61
29886772 2020
33
Spontaneous adrenal hemorrhage and preeclampsia: A case report. 61
31998033 2020
34
Relationship between polymorphisms of CXCL3 gene and preeclampsia. 61
31931644 2020
35
Cardiovascular health and vascular age after severe preeclampsia: A cohort study. 61
31805453 2020
36
Assessment of facility and health worker readiness to provide quality antenatal, intrapartum and postpartum care in rural Southern Nepal. 61
31906938 2020
37
Correlation of elevated levels of lipoprotein(a), high-density lipoprotein and low-density lipoprotein with severity of preeclampsia: a prospective longitudinal study. 61
31304822 2020
38
Sodium Intake during Pregnancy, but Not Other Diet Recommendations Aimed at Preventing Cardiovascular Disease, Is Positively Related to Risk of Hypertensive Disorders of Pregnancy. 61
31504673 2020
39
Association between Serum Homocysteine Levels in Preeclampsia and its Severity among Women in Lagos, South-West Nigeria. 61
32030711 2020
40
Alterations of Several Serum Parameters Are Associated with Preeclampsia and May Be Potential Markers for the Assessment of PE Severity. 61
32025276 2020
41
Maternal, fetal, and neonatal outcomes among different types of hypertensive disorders associating pregnancy needing intensive care management. 61
29914278 2020
42
Complete Hydatidiform Mole and Co-Existing Live Fetus after Intracytoplasmic Sperm Injection: A Case Report and Literature Review. 61
31997691 2020
43
Managing pregnancy-associated clinical emergencies in systemic lupus erythematosus: a case-based approach. 61
31791152 2020
44
Identifying cardiovascular severe maternal morbidity in epidemiologic studies. 61
31971615 2020
45
The effect of folic acid throughout pregnancy among pregnant women at high risk of pre-eclampsia: A randomized clinical trial. 61
31987769 2020
46
In utero exposure to pre-eclampsia as an independent risk factor for long-term respiratory disease. 61
31985889 2020
47
Severe acute maternal morbidity trends in Victoria, 2001-2017. 61
31788786 2019
48
Intravenous magnesium sulfate in the management of severe pre-eclampsia: A randomized study of 12-hour versus 24-hour maintenance dose. 61
31833059 2019
49
Early onset severe preeclampsia and eclampsia in a low-resource setting, Mpilo Central Hospital, Bulawayo, Zimbabwe. 61
31864399 2019
50
Hippo-YAP1 signaling pathway and severe preeclampsia (sPE) in the Chinese population. 61
31841877 2019

Variations for Severe Pre-Eclampsia

Expression for Severe Pre-Eclampsia

Search GEO for disease gene expression data for Severe Pre-Eclampsia.

Pathways for Severe Pre-Eclampsia

Pathways related to Severe Pre-Eclampsia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.99 VEGFA SERPINC1 FN1 FGR F5 APOH
2 11.56 CFH CFB C3
3 11.51 VEGFA VCAM1 MMP9 FN1
4
Show member pathways
11.3 VEGFA VCAM1 MMP9
5 11.18 SERPINC1 F5 CFH CFB C3
6 11.11 MMP9 FN1 FGR
7 10.55 VEGFA SERPINC1 FGR

GO Terms for Severe Pre-Eclampsia

Cellular components related to Severe Pre-Eclampsia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10 VCAM1 SERPINC1 MMP9 GPT FN1 FGR
2 extracellular region GO:0005576 9.89 VEGFA SERPINC1 PGF PAPPA MMP9 LEP
3 endoplasmic reticulum lumen GO:0005788 9.77 SERPINC1 FN1 F5 C3 ALB
4 blood microparticle GO:0072562 9.63 SERPINC1 FN1 CFH CFB C3 ALB
5 platelet alpha granule lumen GO:0031093 9.62 VEGFA FN1 F5 ALB
6 extracellular space GO:0005615 9.55 VEGFA VCAM1 SERPINC1 PGF PAPPA MMP9

Biological processes related to Severe Pre-Eclampsia according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.92 VEGFA PGF LEP FN1 APLN
2 positive regulation of protein phosphorylation GO:0001934 9.78 VEGFA PGF MMP9 C3
3 post-translational protein modification GO:0043687 9.77 SERPINC1 FN1 F5 C3 ALB
4 complement activation GO:0006956 9.73 CFH CFB C3
5 response to hypoxia GO:0001666 9.73 VEGFA VCAM1 PGF LEP
6 female pregnancy GO:0007565 9.71 PGF PAPPA LEP
7 response to nutrient GO:0007584 9.67 VCAM1 SERPINC1 LEP
8 angiogenesis GO:0001525 9.65 VEGFA PGF LEP FN1 APLN
9 lactation GO:0007595 9.58 VEGFA SERPINC1 APLN
10 induction of positive chemotaxis GO:0050930 9.55 VEGFA PGF
11 regulation of blood coagulation GO:0030193 9.51 SERPINC1 APOH
12 positive regulation of mast cell chemotaxis GO:0060754 9.46 VEGFA PGF
13 platelet degranulation GO:0002576 9.35 VEGFA FN1 F5 APOH ALB
14 complement activation, alternative pathway GO:0006957 9.33 CFH CFB C3
15 negative regulation of vasoconstriction GO:0045906 9.32 LEP APLN
16 cellular protein metabolic process GO:0044267 9.1 SERPINC1 PAPPA FN1 F5 C3 ALB

Molecular functions related to Severe Pre-Eclampsia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 VEGFA SERPINC1 MMP9 HLA-G FN1 APOH
2 signaling receptor binding GO:0005102 9.43 LEP HLA-G FN1 FGR C3 APLN
3 vascular endothelial growth factor receptor binding GO:0005172 9.16 VEGFA PGF
4 heparin binding GO:0008201 9.1 VEGFA SERPINC1 PGF FN1 CFH APOH

Sources for Severe Pre-Eclampsia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....